XENON PHARMACEUTICALS INC. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$8M
R&D
$301M
D&A
$3M
Operating Income
$-373M
EBITDA
$-371M
Interest Expense
—
Interest Income
$27M
Other Income/Expense
$1M
Pretax Income
$-345M
Tax Provision
$1M
Net Income
$-346M
Operating Margin
-4974.3%
Net Margin
-4612.1%
Effective Tax Rate
-0.3%
Deferred Tax Assets
$15M
DTA Valuation Allowance
$347M
Tax Credit Carryforwards
$47M
NOL Carryforwards
$932M
ETR (Continuing Operations)
-0.3%
ETR Federal Statutory
15.0%
Operating Lease Cost
$2M
Revenue YoY Variation
—
Income YoY Variation
-33.6%